Royalty Pharma plc

Royalty Pharma plc announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time on the same day. Investors can access conference call information and the live webcast via the company's investor relations website, with a replay available for at least 30 days.

Royalty Pharma plc announced its participation in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for Tuesday, June 9, 2026, at 4:00 p.m. ET, and a live webcast will be available on the company's investor relations website. Royalty Pharma, founded in 1996, is a major buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry.

Royalty Pharma plc, along with its subsidiaries Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC, has entered into a new Revolving Credit Agreement for an unsecured revolving credit facility of $1.8 billion. This new facility, effective May 22, 2026, refinances and replaces the previous credit agreement from September 2021. The facility matures on May 22, 2031, and includes customary covenants such as maintaining specific consolidated leverage, portfolio cash flow, and coverage ratios.

Royalty Pharma plc announced its participation in two upcoming investor conferences in May. The company will present at the BofA Securities 2026 Healthcare Conference on May 13 and the RBC Capital Markets 2026 Global Healthcare Conference on May 19. Webcasts for both events will be available on Royalty Pharma's investor relations website and archived for at least 30 days.

Royalty Pharma plc reported a strong first quarter for 2026, with net income attributable to the company increasing by 23.1% to $294.7 million and basic earnings per share rising to $0.67. Total income and other revenues grew by 11.0% to $630.6 million, while net cash provided by operating activities increased by 20.5% to $718.2 million. The company also acquired $452.4 million in financial royalty assets and repurchased $50.1 million of Class A ordinary shares during the quarter, with $1.7 billion remaining under the repurchase program.

Royalty Pharma plc reported strong financial results for the first quarter of 2026, with Portfolio Receipts growing 10% to $925 million and Royalty Receipts increasing 13% to $887 million. The company also raised its full-year 2026 Portfolio Receipts guidance to a range of $3,325 million to $3,450 million. Key highlights included significant transaction activity, with up to $1.25 billion in new royalty deals, and positive clinical and regulatory developments across its portfolio, such as the FDA approval of Avlayah and positive Phase 3 results for daraxonrasib.

Royalty Pharma plc announced the launch of the Royalty Pharma Translational Prize, an annual award designed to recognize exceptional achievements in translational medicine. The prize aims to honor scientific breakthroughs that successfully bridge fundamental discovery with the development of new medicines, particularly contributions not yet widely recognized. It includes a $1 million award for established scientists whose work has significantly impacted patient lives.

Royalty Pharma plc announced it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time on the same day to discuss the results. Investors can access the webcast and conference call details via the company's investor relations website.

Revolution Medicines announced positive Phase 3 results for daraxonrasib in metastatic pancreatic ductal adenocarcinoma, meeting all primary and key secondary endpoints. This success triggered an additional $250 million funding tranche from Royalty Pharma to Revolution Medicines, bringing Royalty Pharma's total funding to $500 million. With this tranche, Royalty Pharma is now entitled to tiered royalties starting at 4.55% on daraxonrasib sales up to $2 billion. Revolution Medicines plans to submit these data to global regulatory authorities, including the FDA.